Trial Profile
Usefulness of Tolvaptan preventing for excessive body fluid retention after cardiac surgery
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Furosemide
- Indications Oedema; Renal impairment
- Focus Therapeutic Use
- 18 Aug 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 14 Mar 2014 New trial record